Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2016 Jul 12;9:54. doi: 10.1186/s13045-016-0286-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — Meta-analysis of nonhematologic adverse events (AEs) with variable carfilzomib/panobinostat/elotuzumab-containing combination regimens in patients with multiple myeloma. a ≥Grade 3 nonhematologic AEs with carfilzomib combination regimens in patients with relapsed and refractory multiple myeloma. b All grades nonhematologic AEs with carfilzomib combination regimens in patients with relapsed and refractory multiple myeloma. c ≥Grade 3 nonhematologic AEs with panobinostat combination regimens in patients with relapsed and refractory multiple myeloma. d All grades nonhematologic AEs panobinostat combination regimens in patients with relapsed and refractory multiple myeloma. e ≥Grade 3 nonhematologic AEs with elotuzumab combination regimens in patients with relapsed and refractory multiple myeloma. f All grades nonhematologic AEs with elotuzumab combination regimens in patients with relapsed and refractory multiple myeloma. N number of the included trials, CI 95 % confidence interval, Random random effects model